Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06946860 · 4 trials · 12 indications
The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. An AE was considered an TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.
Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin\< 0.8x lower limit of normal (LLN); Hematocrit\< 0.8x LLN; Erythrocytes (Ery.)\< 0.8x LLN; Ery. Mean Corpuscular Volume\< 0.9x LLN; Leukocytes\< 0.6x LLN; Lymphocytes\< 0.8x LLN; Bilirubin\> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase\> 3.0x ULN; Alkaline Phosphatase\> 3.0x ULN; Protein\< 0.8x LLN; Sodium\< 0.95x LLN; Chloride\< 0.9x LLN; Calcium\< 0.9x LLN; Bicarbonate\< 0.9x LLN; Glucose\> 1.5x ULN; C Reactive Protein\> 1.1x ULN; for urinalysis, Urine Glucose ≥1, Ketones ≥1, Urine Protein ≥1, Urine Hemoglobin ≥1, Urobilinogen ≥1, Nitrite ≥1, and Leukocyte ≥1 Esterase ≥1; Hyaline Casts \>1/LPF.
Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) \<50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate \<40 beats per minute (bpm) or \>120 bpm.
ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470\< value ≤480 msec, 480\< value ≤500 msec, value \>500 msec, and 30\< change ≤60 msec, change \>60 msec.
| Arm | Type | Description |
|---|---|---|
| Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 Treatment | EXPERIMENTAL | subcutaneous injection |
| Double-Blind Placebo Treatment followed by Open-Label PF-06946860 Treatment | PLACEBO_COMPARATOR | subcutaneous injection |
| PF-06946860 | EXPERIMENTAL | subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | Single subcutaneous administration of placebo |
| Cohort 1 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo |
| Cohort 2 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo |
| Cohort 3 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo |
| Cohort 4 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo |
| Cohort 5 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo |
| Cohort 6 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo |
| Cohort 7 | EXPERIMENTAL | Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo |
| Optional: Cohort 8 | EXPERIMENTAL | Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects |
| Name | Type | Description |
|---|---|---|
| PF-06946860 | DRUG | subcutaneous injection |
| Placebo for PF-06946860 | DRUG | subcutaneous injection |
| Placebo | OTHER | Placebo administered subcutaneously |
Key Inclusion Criteria: * Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered advanced. * Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite...
PF-06946860 is an investigational small molecule being studied for use in cachexia, anorexia, and loss of appetite in patients with advanced cancers such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, prostate cancer, breast cancer, and ovarian cancer. It has also been studied in healthy volunteers.
PF-06946860 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PF-06946860 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All four clinical trials listed for the drug are Phase 1 studies and have been completed.
PF-06946860 has been studied in four completed Phase 1 trials. NCT03599063 and NCT03974776 tested single doses in healthy adults. NCT04299048 assessed repeated doses in patients with cancer and cachexia. NCT04803305 compared repeated doses against placebo on appetite in advanced cancer patients with anorexia.
PF-06946860 is a small molecule being investigated for its effects on appetite and body wasting in cancer patients. Its specific molecular target has not been disclosed in the available clinical trial information.